A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturers responsible for batch release Accord Healthcare Ltd.
Sage House 319 Pinner road
North Harrow, Middx HA1 4HF United Kingdom
Pharmacare Premium Ltd
HHF 003, Hal Far Industrial Estate Birzebbugia, BBG 3000
- Ifirmasta (irbesartan krka) - Krka, d.d., Novo mesto
- Repaglinide krka - Krka, d.d., Novo mesto
- Vizarsin - Krka, d.d., Novo mesto
- Tolura - Krka, d.d., Novo mesto
- Paglitaz - Krka, d.d., Novo mesto
Prescription drugs listed. Manufacturer: "Krka, d.d., Novo mesto"
KRKA, d.d., Novo mesto Šmarješka cesta 6
8501 Novo mesto Slovenia
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
•Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
•Risk Management Plan (RMP)